Tokyo Tape
Sign in
← Otsuka Holdings

Quarterly report · Q3

4578.TEDINET S100PGE4
Period2022-01-01 → 2022-09-30
Filed2022-11-02
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥1.27T2022-01-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥451.8bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Revenue¥1.50T2021-01-01 → 2021-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥1.11T2021-01-01 → 2021-09-30Cons.Revenue IFRS
Revenue¥388.6bn2021-07-01 → 2021-09-30dCons.Revenue IFRS
Operating income¥114.8bn2022-01-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥47.7bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Operating income¥158.1bn2021-01-01 → 2021-09-30Cons.Operating profit loss IFRS
Operating income¥47.0bn2021-07-01 → 2021-09-30dCons.Operating profit loss IFRS
Profit before tax¥146.0bn2022-01-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥53.2bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Profit before tax¥163.6bn2021-01-01 → 2021-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥166.3bn2021-01-01 → 2021-09-30Cons.Profit loss before tax IFRS
Profit before tax¥47.1bn2021-07-01 → 2021-09-30dCons.Profit loss before tax IFRS
Net income (owners)¥111.0bn2022-01-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥41.3bn2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥125.5bn2021-01-01 → 2021-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥126.6bn2021-01-01 → 2021-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥35.2bn2021-07-01 → 2021-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥113.9bn2022-01-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥42.4bn2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Net income¥130.0bn2021-01-01 → 2021-09-30Cons.Profit loss IFRS
Net income¥36.3bn2021-07-01 → 2021-09-30dCons.Profit loss IFRS
Total assets¥3.19Tat 2022-09-30Cons.Assets IFRS
Total assets¥2.82Tat 2021-12-31Cons.Assets IFRS
Total assets¥2.82Tat 2021-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥853.3bnat 2022-09-30Cons.Liabilities IFRS
Total liabilities¥775.7bnat 2021-12-31Cons.Liabilities IFRS
Net assets / equity¥2.33Tat 2022-09-30Cons.Equity IFRS
Net assets / equity¥2.05Tat 2021-12-31Cons.Equity IFRS
Net assets / equity¥2.02Tat 2021-09-30Cons.Equity IFRS
Net assets / equity¥1.88Tat 2020-12-31dCons.Equity IFRS
Equity (owners)¥2.30Tat 2022-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥2.01Tat 2021-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.98Tat 2021-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥477.3bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥410.7bnat 2021-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥448.7bnat 2021-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥356.9bnat 2020-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥171.1bn2022-01-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥228.9bn2021-01-01 → 2021-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥197.2bn2021-01-01 → 2021-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥60.4bn2022-01-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥95.3bn2021-01-01 → 2021-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥33.0bn2021-01-01 → 2021-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥84.0bn2022-01-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥95.8bn2021-01-01 → 2021-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥83.7bn2021-01-01 → 2021-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥204.652022-01-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥76.062022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥231.322021-01-01 → 2021-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥233.52021-01-01 → 2021-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥64.972021-07-01 → 2021-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥204.632022-01-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥76.042022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥231.152021-01-01 → 2021-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥233.342021-01-01 → 2021-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥64.82021-07-01 → 2021-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio72.1%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio71.3%at 2021-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio70.5%at 2021-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 88
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-01-01 → 2022-09-30¥126.1bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-07-01 → 2022-09-30¥43.4bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-01-01 → 2022-09-30¥94.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-07-01 → 2022-09-30¥31.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-01-01 → 2022-09-30¥31.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-07-01 → 2022-09-30¥11.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-01-01 → 2022-09-30¥9.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-07-01 → 2022-09-30¥2.0bn
Reconciling Itemsreconcilingrevenue2022-01-01 → 2022-09-30−¥32.0bn
Reconciling Itemsreconcilingrevenue2022-07-01 → 2022-09-30−¥11.9bn
Reconciling Itemsreconcilingrevenue intersegment2022-01-01 → 2022-09-30−¥32.0bn
Reconciling Itemsreconcilingrevenue intersegment2022-07-01 → 2022-09-30−¥11.9bn
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-09-30−¥34.8bn
Reconciling Itemsreconcilingsegment profit2022-07-01 → 2022-09-30−¥12.0bn
jpcrp040300-q3r_E21183-000Consumer Productsreportable segmentrevenue2022-01-01 → 2022-09-30¥27.0bn
jpcrp040300-q3r_E21183-000Consumer Productsreportable segmentrevenue2022-07-01 → 2022-09-30¥10.3bn
jpcrp040300-q3r_E21183-000Consumer Productsreportable segmentrevenue external2022-01-01 → 2022-09-30¥27.0bn
jpcrp040300-q3r_E21183-000Consumer Productsreportable segmentrevenue external2022-07-01 → 2022-09-30¥10.3bn
jpcrp040300-q3r_E21183-000Consumer Productsreportable segmentrevenue intersegment2022-01-01 → 2022-09-30¥18m
jpcrp040300-q3r_E21183-000Consumer Productsreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥12m
jpcrp040300-q3r_E21183-000Consumer Productsreportable segmentsegment profit2022-01-01 → 2022-09-30¥5.6bn
jpcrp040300-q3r_E21183-000Consumer Productsreportable segmentsegment profit2022-07-01 → 2022-09-30¥3.8bn
jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segmentrevenue2022-01-01 → 2022-09-30¥325.6bn
jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segmentrevenue2022-07-01 → 2022-09-30¥119.9bn
jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segmentrevenue external2022-01-01 → 2022-09-30¥325.6bn
jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segmentrevenue external2022-07-01 → 2022-09-30¥119.9bn
jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segmentrevenue intersegment2022-01-01 → 2022-09-30¥18m
jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥7m
jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segmentsegment profit2022-01-01 → 2022-09-30¥49.8bn
jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segmentsegment profit2022-07-01 → 2022-09-30¥21.6bn
jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segmentrevenue2022-01-01 → 2022-09-30¥819.3bn
jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segmentrevenue2022-07-01 → 2022-09-30¥290.0bn
jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segmentrevenue external2022-01-01 → 2022-09-30¥819.3bn
jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segmentrevenue external2022-07-01 → 2022-09-30¥290.0bn
jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segmentsegment profit2022-01-01 → 2022-09-30¥84.5bn
jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segmentsegment profit2022-07-01 → 2022-09-30¥32.3bn
—segment totalrevenue2022-01-01 → 2022-09-30¥1.30T
—segment totalrevenue2022-07-01 → 2022-09-30¥463.7bn
—segment totalrevenue external2022-01-01 → 2022-09-30¥1.27T
—segment totalrevenue external2022-07-01 → 2022-09-30¥451.8bn
—segment totalrevenue intersegment2022-01-01 → 2022-09-30¥32.0bn
—segment totalrevenue intersegment2022-07-01 → 2022-09-30¥11.9bn
—segment totalsegment profit2022-01-01 → 2022-09-30¥149.7bn
—segment totalsegment profit2022-07-01 → 2022-09-30¥59.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2021-01-01 → 2021-09-30¥110.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2021-07-01 → 2021-09-30¥36.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2021-01-01 → 2021-09-30¥82.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2021-07-01 → 2021-09-30¥26.5bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2021-01-01 → 2021-09-30¥28.4bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2021-07-01 → 2021-09-30¥10.4bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2021-01-01 → 2021-09-30¥12.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2021-07-01 → 2021-09-30¥2.8bn
Reconciling Itemsreconcilingrevenue2021-01-01 → 2021-09-30−¥28.5bn
Reconciling Itemsreconcilingrevenue2021-07-01 → 2021-09-30−¥10.4bn
Reconciling Itemsreconcilingrevenue intersegment2021-01-01 → 2021-09-30−¥28.5bn
Reconciling Itemsreconcilingrevenue intersegment2021-07-01 → 2021-09-30−¥10.4bn
Reconciling Itemsreconcilingsegment profit2021-01-01 → 2021-09-30−¥33.6bn
Reconciling Itemsreconcilingsegment profit2021-07-01 → 2021-09-30−¥11.8bn
jpcrp040300-q3r_E21183-000Consumer Productsreportable segmentrevenue2021-01-01 → 2021-09-30¥24.1bn
jpcrp040300-q3r_E21183-000Consumer Productsreportable segmentrevenue2021-07-01 → 2021-09-30¥8.9bn
jpcrp040300-q3r_E21183-000Consumer Productsreportable segmentrevenue external2021-01-01 → 2021-09-30¥24.1bn
jpcrp040300-q3r_E21183-000Consumer Productsreportable segmentrevenue external2021-07-01 → 2021-09-30¥8.9bn
jpcrp040300-q3r_E21183-000Consumer Productsreportable segmentrevenue intersegment2021-01-01 → 2021-09-30¥17m
jpcrp040300-q3r_E21183-000Consumer Productsreportable segmentrevenue intersegment2021-07-01 → 2021-09-30¥8m
jpcrp040300-q3r_E21183-000Consumer Productsreportable segmentsegment profit2021-01-01 → 2021-09-30¥5.8bn
jpcrp040300-q3r_E21183-000Consumer Productsreportable segmentsegment profit2021-07-01 → 2021-09-30¥2.5bn
jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segmentrevenue2021-01-01 → 2021-09-30¥280.1bn
jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segmentrevenue2021-07-01 → 2021-09-30¥104.8bn
jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segmentrevenue external2021-01-01 → 2021-09-30¥280.0bn
jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segmentrevenue external2021-07-01 → 2021-09-30¥104.7bn
jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segmentrevenue intersegment2021-01-01 → 2021-09-30¥33m
jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segmentrevenue intersegment2021-07-01 → 2021-09-30¥12m
jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segmentsegment profit2021-01-01 → 2021-09-30¥45.8bn
jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segmentsegment profit2021-07-01 → 2021-09-30¥19.0bn
jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segmentrevenue2021-01-01 → 2021-09-30¥721.0bn
jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segmentrevenue2021-07-01 → 2021-09-30¥248.5bn
jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segmentrevenue external2021-01-01 → 2021-09-30¥721.0bn
jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segmentrevenue external2021-07-01 → 2021-09-30¥248.5bn
jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segmentsegment profit2021-01-01 → 2021-09-30¥128.0bn
jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segmentsegment profit2021-07-01 → 2021-09-30¥34.5bn
—segment totalrevenue2021-01-01 → 2021-09-30¥1.14T
—segment totalrevenue2021-07-01 → 2021-09-30¥399.0bn
—segment totalrevenue external2021-01-01 → 2021-09-30¥1.11T
—segment totalrevenue external2021-07-01 → 2021-09-30¥388.6bn
—segment totalrevenue intersegment2021-01-01 → 2021-09-30¥28.5bn
—segment totalrevenue intersegment2021-07-01 → 2021-09-30¥10.4bn
—segment totalsegment profit2021-01-01 → 2021-09-30¥191.8bn
—segment totalsegment profit2021-07-01 → 2021-09-30¥58.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 835
ItemContextValueUnit
Revenue IFRSPrior1YTDDuration_ReconcilingItemsMember-28496000000JPY
Revenue IFRSPrior1YTDDuration1107417000000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q3r_E21183-000PharmaceuticalsReportableSegmentMember127955000000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q3r_E21183-000NutraceuticalsReportableSegmentMember45789000000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q3r_E21183-000ConsumerProductsReportableSegmentMember5781000000JPY
Operating profit loss IFRSPrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember12225000000JPY
Operating profit loss IFRSPrior1YTDDuration_ReportableSegmentsMember191751000000JPY
Operating profit loss IFRSPrior1YTDDuration_ReconcilingItemsMember-33620000000JPY
Operating profit loss IFRSPrior1YTDDuration158130000000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q3r_E21183-000PharmaceuticalsReportableSegmentMember819334000000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q3r_E21183-000NutraceuticalsReportableSegmentMember325612000000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q3r_E21183-000ConsumerProductsReportableSegmentMember26987000000JPY
Revenue from external customers IFRSCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember94184000000JPY
Revenue from external customers IFRSCurrentYTDDuration_ReportableSegmentsMember1266119000000JPY
Revenue from external customers IFRSCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenue from external customers IFRSCurrentYTDDuration1266119000000JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q3r_E21183-000PharmaceuticalsReportableSegmentMember－JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q3r_E21183-000NutraceuticalsReportableSegmentMember18000000JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q3r_E21183-000ConsumerProductsReportableSegmentMember18000000JPY
Intersegment revenue IFRSCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember31915000000JPY
Intersegment revenue IFRSCurrentYTDDuration_ReportableSegmentsMember31952000000JPY
Intersegment revenue IFRSCurrentYTDDuration_ReconcilingItemsMember-31952000000JPY
Intersegment revenue IFRSCurrentYTDDuration－JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q3r_E21183-000PharmaceuticalsReportableSegmentMember819334000000JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q3r_E21183-000NutraceuticalsReportableSegmentMember325631000000JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q3r_E21183-000ConsumerProductsReportableSegmentMember27006000000JPY
Revenue IFRSCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember126099000000JPY
Revenue IFRSCurrentYTDDuration_ReportableSegmentsMember1298072000000JPY
Revenue IFRSCurrentYTDDuration_ReconcilingItemsMember-31952000000JPY
Revenue IFRSCurrentYTDDuration1266119000000JPY
Operating profit loss IFRSCurrentYTDDuration_jpcrp040300-q3r_E21183-000PharmaceuticalsReportableSegmentMember84472000000JPY
Operating profit loss IFRSCurrentYTDDuration_jpcrp040300-q3r_E21183-000NutraceuticalsReportableSegmentMember49760000000JPY
Operating profit loss IFRSCurrentYTDDuration_jpcrp040300-q3r_E21183-000ConsumerProductsReportableSegmentMember5596000000JPY
Operating profit loss IFRSCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember9855000000JPY
Operating profit loss IFRSCurrentYTDDuration_ReportableSegmentsMember149684000000JPY
Operating profit loss IFRSCurrentYTDDuration_ReconcilingItemsMember-34835000000JPY
Operating profit loss IFRSCurrentYTDDuration114848000000JPY
Revenue from external customers IFRSPrior1QuarterDuration_jpcrp040300-q3r_E21183-000PharmaceuticalsReportableSegmentMember248506000000JPY
Revenue from external customers IFRSPrior1QuarterDuration_jpcrp040300-q3r_E21183-000NutraceuticalsReportableSegmentMember104748000000JPY
Revenue from external customers IFRSPrior1QuarterDuration_jpcrp040300-q3r_E21183-000ConsumerProductsReportableSegmentMember8896000000JPY
Revenue from external customers IFRSPrior1QuarterDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember26451000000JPY
Revenue from external customers IFRSPrior1QuarterDuration_ReportableSegmentsMember388602000000JPY
Revenue from external customers IFRSPrior1QuarterDuration_ReconcilingItemsMember－JPY
Revenue from external customers IFRSPrior1QuarterDuration388602000000JPY
Intersegment revenue IFRSPrior1QuarterDuration_jpcrp040300-q3r_E21183-000PharmaceuticalsReportableSegmentMember－JPY
Intersegment revenue IFRSPrior1QuarterDuration_jpcrp040300-q3r_E21183-000NutraceuticalsReportableSegmentMember12000000JPY
Intersegment revenue IFRSPrior1QuarterDuration_jpcrp040300-q3r_E21183-000ConsumerProductsReportableSegmentMember8000000JPY
Intersegment revenue IFRSPrior1QuarterDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember10407000000JPY
Intersegment revenue IFRSPrior1QuarterDuration_ReportableSegmentsMember10428000000JPY
Intersegment revenue IFRSPrior1QuarterDuration_ReconcilingItemsMember-10428000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2021-12-31pass rounding
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-01-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-07-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-01-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-01-01/2021-09-30pass
statement vs summary · revenueconsolidated 2021-07-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2021-12-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass